Histological changes in patients who developed hepatocellular carcinoma after hepatitis C virus eradication by interferon-based therapy

被引:1
作者
Kawaguchi, Toshihiro [1 ]
Ide, Tatsuya [1 ]
Kondo, Reiichiro [2 ]
Nomura, Yoriko [3 ]
Arinaga-Hino, Teruko [1 ]
Kuwahara, Reiichiro [1 ]
Amano, Keisuke [1 ]
Sano, Tomoya [1 ]
Akiba, Jun [2 ]
Ohshima, Koichi [2 ]
Yano, Hirohisa [2 ]
Torimura, Takuji [1 ]
机构
[1] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan
[2] Kurume Univ, Sch Med, Dept Pathol, Kurume, Fukuoka 8300011, Japan
[3] Kurume Univ, Sch Med, Dept Surg, Kurume, Fukuoka 8300011, Japan
关键词
hepatocellular carcinoma; chronic hepatitis C; sustained virological response; histological inflammation; forkhead box P3; SUSTAINED VIROLOGICAL RESPONSE; REGULATORY T-CELLS; PERIPHERAL-BLOOD; FOLLOW-UP; INFLAMMATION; RISK; PROGRESSION; FIBROSIS; LYMPHOCYTES; CD4(+);
D O I
10.3892/etm.2019.8024
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Although the incidence of hepatocellular carcinoma (HCC) occurring after hepatitis C virus (HCV) eradication has decreased, there are still reports of hepatocarcinogenesis. The present study investigated the histological changes of non-cancerous liver tissue obtained prior to interferon (IFN) therapy and after HCC development. A total of 669 HCV-infected Japanese patients who achieved sustained virological response (SVR) by IFN-based therapy were retrospectively enrolled. Of these, the present study investigated 18 patients who developed HCC after IFN-based SVR. Specimens from 9 of 18 patients were available for histological comparisons prior to IFN therapy and following HCC development. Of these 9 patients, the specimens of 5 individuals were compared via immunohistochemical staining [CD3, CD4, CD8, CD20, forkhead box P3 (FOXP3), transforming growth factor-beta 1 and granzyme B]. The current study included 6 control patients with HCV-associated chronic liver disease who subsequently developed HCC (non-SVR-HCC group). Mann-Whitney and Wilcoxon tests were used to compare groups. Bonferroni correction was used for multiple comparisons. P<0.05 was used as a critical P-value, and following Bonferroni's correction, P<0.017 was considered to indicate a statistically significant difference. In the 9 patients examined, continuous inflammation and fibrosis were observed after HCC development. There was also a significant decrease in the positive rate of FOXP3 in all 5 patients at the time of HCC development compared with that prior to IFN therapy (P=0.0084). Additionally, there was a significant difference in the positive rate of FOXP3 between the 5 patients after HCC development and the control individuals (P=0.0022). In patients who developed HCC after IFN-based SVR, the frequency of FOXP3 decreased, but inflammation and fibrosis remained. The extent of the reduction of FOXP3 differed in patients who developed HCC in the presence of HCV. Inflammation and fibrosis remained for a long duration after SVR, which may be associated with hepatocarcinogenesis.
引用
收藏
页码:3991 / 4001
页数:11
相关论文
共 40 条
[1]   Effect of Aging on Risk for Hepatocellular Carcinoma in Chronic Hepatitis C Virus Infection [J].
Asahina, Yasuhiro ;
Tsuchiya, Kaoru ;
Tamaki, Nobuharu ;
Hirayama, Itsuko ;
Tanaka, Tomohiro ;
Sato, Mitsuaki ;
Yasui, Yutaka ;
Hosokawa, Takanori ;
Ueda, Ken ;
Kuzuya, Teiji ;
Nakanishi, Hiroyuki ;
Itakura, Jun ;
Takahashi, Yuka ;
Kurosaki, Masayuki ;
Enomoto, Nobuyuki ;
Izumi, Namiki .
HEPATOLOGY, 2010, 52 (02) :518-527
[2]   Cytotoxic CD4+ T cells in viral hepatitis [J].
Aslan, N. ;
Yurdaydin, C. ;
Wiegand, J. ;
Greten, T. ;
Ciner, A. ;
Meyer, M. F. ;
Heiken, H. ;
Kuhlmann, B. ;
Kaiser, T. ;
Bozkaya, H. ;
Tillmann, H. L. ;
Bozdayi, A. M. ;
Manns, M. P. ;
Wedemeyer, H. .
JOURNAL OF VIRAL HEPATITIS, 2006, 13 (08) :505-514
[3]   Portal Chronic Inflammation in Nonalcoholic Fatty Liver Disease (NAFLD): A Histologic Marker of Advanced NAFLD-Clinicopathologic Correlations from the Nonalcoholic Steatohepatitis Clinical Research Network [J].
Brunt, Elizabeth M. ;
Kleiner, David E. ;
Wilson, Laura A. ;
Unalp, Aynur ;
Behling, Cynthia E. ;
Lavine, Joel F. ;
Neuschwander-Tetri, Brent A. .
HEPATOLOGY, 2009, 49 (03) :809-820
[4]   Differential CD4+ and CD8+ T-cell responsiveness in hepatitis C virus infection [J].
Chang, KM ;
Thimme, R ;
Melpolder, JJ ;
Oldach, D ;
Pemberton, J ;
Moorhead-Loudis, J ;
McHutchison, JG ;
Alter, HJ ;
Chisari, FV .
HEPATOLOGY, 2001, 33 (01) :267-276
[5]   Portal lymphocytic infiltrate in alcoholic liver disease [J].
Colombat, M ;
Charlotte, F ;
Ratziu, V ;
Poynard, T .
HUMAN PATHOLOGY, 2002, 33 (12) :1170-1174
[6]  
DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629
[7]  
Dimitropoulou D, 2011, IN VIVO, V25, P833
[8]  
Enokimura N, 2003, ANTICANCER RES, V23, P593
[9]   TGF-BETA IN LIVER DEVELOPMENT, REGENERATION, AND CARCINOGENESIS [J].
FAUSTO, N ;
MEAD, JE ;
GRUPPUSO, PA ;
BRAUN, L .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1990, 593 :231-242
[10]   Clinical, Virologic, Histologic, and Biochemical Outcomes After Successful HCV Therapy: A 5-Year Follow-up of 150 Patients [J].
George, Sarah L. ;
Bacon, Bruce R. ;
Brunt, Elizabeth M. ;
Mihindukulasuriya, Kusal L. ;
Hoffmann, Joyce ;
Di Bisceglie, Adrian M. .
HEPATOLOGY, 2009, 49 (03) :729-738